Articles

Export this record

Export selected records

Export record to excel

File type to download

Beta version

Record title

440 Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer

Record identifier

TN_cdi_proquest_journals_2552999478

440 Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer

ACCESS
https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2552999478

440 Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer

Full title

440 Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer

Publisher

London: BMJ Publishing Group LTD

Journal title

Journal for immunotherapy of cancer, 2020, Vol.8 (Suppl 3), p.A267-A268

Record Identifier

TN_cdi_proquest_journals_2552999478

Language

English

Formats

Publication information

Publisher

Subjects

Subjects and topics

Chemotherapy Lung cancer

More information

SCOPE AND CONTENTS

Contents

ALTERNATIVE TITLES

Full title

Identifiers

PRIMARY IDENTIFIERS

Record Identifier

TN_cdi_proquest_journals_2552999478

Permalink

https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2552999478

OTHER IDENTIFIERS

E-ISSN

DOI

How to access this item

Online

1 item

How to access?

Login with a Library card